What is the Piggy-Back rule? ↑Top The Piggy-Back rule stipulates that a security is eligible for quoting under Rule 15c2-11 without the submission of a Form 211. Any authorized market maker may begin quoting piggy-back eligible securities at any point in time. The "piggy-back" exception is based on a market maker publishing quotations for a security in an applicable interdealer quotation system (OTC Link or the OTCBB) on at least 12 business days during the preceding 30 calendar days, with not more than four consecutive business days without quotations. And Do I have to file a Form 211 for a security that has been delisted from the New York Stock Exchange, NASDAQ or NYSE-AMEX? ↑Top Yes – listing on NYSE, NASDAQ or NYSE-AMEX does not exempt a Market Maker from filing a Form 211. If, however, the security was quoted on OTC Link prior to the delisting it may be considered "piggyback" eligible.
By changing venues from Grey Market to OTC Link(R), the Company is able to provide further transparency and financial reporting to our US based investors allowing them access to more information and hence a greater comfort in investing in Theralase. As Theralase delivers on its corporate milestones in both divisions in 2014 and 2015, it would be reasonable to expect the interest in acquiring Theralase common stock to increase among US based investors, leading Theralase to pursue full financial reporting and disclosure to the SEC to allow an eventual listing on a major US exchange, such as NASDAQ
It's like an old woman all dried up . Need some trial results
*** A Form 211 is not required for listing on NASDAQ; however, the average time of approval for listing on NASDAQ is 6-8 weeks. http://www.otcbb.com/aboutOTCBB/comparison.stm
Don't worry I'm waiting until at least 4 dollars on Nasdaq and my XBIO multi millionaire status. A word from our friends on the Russian bb http://translate.google.co.uk/translate?hl=en&sl=ru&u=http://mfd.ru/forum/thread/%3Fid%3D62145&prev=/search%3Fq%3Derepoxen%26start%3D10%26client%3Dsafari%26sa%3DN%26hl%3Den-gb%26biw%3D1024%26bih%3D672%26tbs%3Dqdr:w
Next Nasdaq Trial results
Thought as much, just wanted someone with better Russian than me to confirm
shalilore (Wednesday April 16, 2014) Agency by the Food and Drug redstvami U.S. (FDA) approved the drug on March 9 Benlysta (belimumab) for the treatment of adult patients with active systemic lupus erythematosus (SLE)-positive auto-antibodies that receive standard therapy (corticosteroids, immunosuppressive , NSAIDs and antialyariynye drugs). Clinical trials of the drug on 675 patients showed that it works better than traditional chemotherapy, as is aimed at the genetic mutation existing half of cancer patients. Reported the press office of Human Stem Cells Institute (HSCI). More than half of people 65 years of age suffer from the development of the disease in one or both eyes. It is expected that the drug will come to market in the latter half of 2013. Psychiatric reactions (mainly depression, insomnia and anxiety) were more frequent in the case of belimumab (16%) than placebo (12%). Pomalyst drug acts as a stimulant of immune cells that are able to kill cancer cells and suppress. Previously approved by the FDA for the endovascular treatment of aneurysms and penetrating ulcers of the descending thoracic aorta, the stent-graft Valiant Captivia widely used in the U.S. since May 2012. The preparation is based on Oncohist recombinant histone H1 (cell nuclear protein required for the assembly and packaging of strands of DNA into the chromosomes). Pancreatic cancer - one of the most dangerous cancer. A new drug for the treatment of HIV has shown its effectiveness even in patients whose previous treatment showed his helplessness. It was found that acyclovir (a treatment for herpes) reduced the risk of progression of HIV infection by 16%. Scientists from Tel Aviv University have created a drug that blocks the growth and spread of cancer cells. Swelling in the abdomen, usually accompanied by a pronounced smooth muscle spasm, nausea, vomiting and diarrhea. Almost half of the patients receiving Darunavir, the number of copies of the virus dropped to 50 copies per milliliter - the smallest recorded concentration. Patients receiving the drug for four weeks significantly improved their condition. Psoriasis - a chronic skin disease that affects the skin, elbows, joints. According to ABC News, the drug is readily available in the country and forms a strong dependence.
If you had 176 old shares you will now have 56. So you have at least doubled your money and nearly tripled it. There was a share cosolidation so dont get too carried away. itd about 28p
http://www.massbio.org/events/calendar/2534-around_the_world_in_120_days_europe_101-/event_detail
Academic session Wednesday, April 2, 2014 at 14 h 00 Salle des Actes Faculty of Pharmaceutical and Biological Sciences Paris-Descartes University 4 av. 75006 Paris Observatory http://www.acadpharm.org/dos_public/OJ_sEance_2014.04.02_VF.pdf
"Recent developments in the engineering of pharmaceutical proteins with particularly polysialylation as an alternative to PEGylation " Alexander G ABIBOV , Professor of Biochemistry at the State University Lomonosov Moscow Director Immunobiotechnologie of laboratory-Shemiakine Ovshinnikov Institute Correspondent foreign qualification the National Academy of Pharmacy, corresponding member of the Academy of Sciences of Russia, President the Society of Biochemistry, Moscow, Russia The covalent modification of proteins by recombinant soluble biocompatible polymer is a way safer to increase the performance of these proteins for therapeutic uses [1]. Among these methods, the coupling of polysialic acid (PSA), a linear homopolymer, hydrophilic, and non-toxic non-immunogenic N-acetylneuraminic acid (sialic acid) and peptides to proteins pharmaceuriques increases stability and extends their lifetime in the bloodstream [2-4]. In the case of asparaginase and insulin, it was also shown that polysialylation reduced immunogenicity and antéginicité non-human therapeutic proteins. Moreover, unlike other hydrophilic polymers (eg, the polyethylene glycol) [5], the PSAs are less viscous, biodegradable, and their products of degradation exhibit no toxicity [3, 4]. Xenetic society has developed a patented process, PolyXen ®, using the PSA to improve the pharmacokinetics (PK) and pharmacodynamics (PD) of the product biopharmaceuticals. In the present communication we report the effect of polysialylation on several proteins recombinant pharmaceutical interest: gut hormone oxyntomodulin (OXM), the hérythropoiétine human (rhEPO), insulin and human butyrylcholinesterase (rBuChE). The genetic constructs and the expression of these proteins as well as polysialylation were carried out in close cooperation with the Institute Bioorganic Chemistry Shemyakin-Ovshinnikov Academy of Sciences of Russia, and companies pharmaceutical Xenetic Bioscience Inc, OAO Pharmasyntez and the Institute of Structural Biology in Grenoble. The recombinant gut hormone oxyntomodulin (OXM). The OXM is a satiety signal in humans and it has a therapeutic potential in the control of appetite. The natural form of this hormone has a duration of extremely short life in the bloodstream (5-10 min), a single-acting form This prolonged therapeutic interest. We have achieved this goal with a high yield combining the PSA oxydé14 kDa on its N-terminal lysine residues leaving intact. The PSA-conjugate OXM 18 kDa is completely resistant dipeptidylaminopeptidase (DPP-IV) enzyme responsible for the rapid inactivation of OXM in vivo half-life is approximately 36 hours in humans in injection subcutaneous. In mice, administration of this conjugate at a dose of 15  g / kg reduced the consumption food mice stably for 8h. Studies in humans are in phase I: a dose of 1.5 mg / kg results in an increase of the AUC of endogenous insulin almost two-fold compared with witnesses
http://m.europe.wsj.com/articles/SB10001424052702304418404579464993158480338?mg=reno64-wsj Are we piggybacking
http://www.masscec.com/events/polysialylation-next-generation-therapeutics
My bad
The PDF as soon As I posted it. Classic company releasing news before xbio probably, Did anyone save a copy